Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 8/20 | 0.40 |
| ▸ | HTR2A known ✓ | P28223 | 7/20 | 0.40 |
| ▸ | HTR2B | P41595 | 8/20 | 0.40 |
| ▸ | PNMT | P11086 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MELK | Q14680 | 1/20 | 0.31 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12361257 | 0.91 | HTR2C (0.48) | HTR2CHTR2BHTR2APNMTADRA2A | |
| Succinic Acid SCHEMBL2253992 | 0.90 | HTR2A (0.43) | HTR2CHTR2BHTR2APNMTADRA2A | |
| Succinic Acid SCHEMBL2257296 | 0.84 | HTR2A (0.36) | HTR2CHTR2BHTR2APNMTADRA2A | |
| SCHEMBL2256449 | 0.81 | HTR2C (0.50) | HTR2CHTR2BHTR2APNMTADRA2A | |
| Succinic Acid SCHEMBL2254543 | 0.80 | HTR2A (0.40) | HTR2CHTR2BHTR2AS1PR5 | |
| Succinic Acid SCHEMBL2257679 | 0.80 | HTR2A (0.40) | HTR2CHTR2BHTR2APNMTADRA2A | |
| Succinic Acid SCHEMBL2259012 | 0.79 | HTR2A (0.39) | HTR2CHTR2BHTR2APNMTADRA2A | |
| Succinic Acid SCHEMBL2258953 | 0.79 | HTR2A (0.39) | HTR2CHTR2BHTR2APNMTADRA2A | |
| Succinic Acid SCHEMBL2256538 | 0.78 | MAPT (0.42) | HTR2CHTR2BHTR2AALDH1A1MAPT | |
| Succinic Acid SCHEMBL2257456 | 0.78 | HTR2A (0.38) | HTR2CHTR2BHTR2APNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994163-B2 | e.g. 3-tert-Butoxycarbonyl-7-chloro-6-chloromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; serotonin receptor agonist; antidepressant, anxiolytic agent; obesity, obsessive compulsive disorder | ELI LILLY AND COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| EP-1924560-B1 | 6-SUBSTITUTED- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080255092-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255092-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR3C, HTR3A | HTR2C 1/4885HTR2A 10/4885HTR2B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.